Cargando…
Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes
BACKGROUND: Malignant peripheral nerve sheath tumor (MPNST) is an aggressive sarcoma with few treatment options. Tumor immune state has not been characterized in MPNST, and is important in determining response to immune checkpoint blockade. Our aim was to evaluate the expression of programmed death-...
Autores principales: | Shurell, Elizabeth, Singh, Arun S., Crompton, Joseph G., Jensen, Sarah, Li, Yunfeng, Dry, Sarah, Nelson, Scott, Chmielowski, Bartosz, Bernthal, Nicholas, Federman, Noah, Tumeh, Paul, Eilber, Fritz C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325443/ https://www.ncbi.nlm.nih.gov/pubmed/27588404 http://dx.doi.org/10.18632/oncotarget.11734 |
Ejemplares similares
-
Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma
por: Shurell, Elizabeth, et al.
Publicado: (2016) -
Gender dimorphism and age of onset in malignant peripheral nerve sheath tumor preclinical models and human patients
por: Shurell, Elizabeth, et al.
Publicado: (2014) -
Tumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model
por: Kawaguchi, Kei, et al.
Publicado: (2016) -
Safety and Efficacy of Stereotactic Body Radiation Therapy in the Treatment of Pulmonary Metastases from High Grade Sarcoma
por: Mehta, Niraj, et al.
Publicado: (2013) -
Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model
por: Kawaguchi, Kei, et al.
Publicado: (2016)